EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation

Darren M Brenner, Amol Sharma, Satish S C Rao, Adam P Laitman, Zeev Heimanson, Christopher Allen, Gregory S Sayuk

Digestive Diseases and Sciences · 2024

DOI: 10.1007/s10620-024-08330-y ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Darren M Brenner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Darren.br…. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Constipation, Abdominal Pain, Natriuretic Peptides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Salix Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bloating is a bothersome symptom in irritable bowel syndrome with constipation (IBS-C). AIM: To evaluate plecanatide efficacy in patients with IBS-C stratified by bloating intensity. METHODS: Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed. Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]). Assessments included change from baseline in bloating, abdominal pain, and complete spontaneous bowel movement (CSBM) frequency. Abdominal pain and bloating composite responders were defined as patients with ≥ 30% improvement from baseline in both bloating and abdominal pain at Week 12. RESULTS: At baseline, 1104/1436 patients with IBS-C (76.9%) reported moderate-to-severe bloating. In the moderate-to-severe bloating subgroup, plecanatide significantly reduced bloating severity versus placebo (least-squares mean change [LSMC]: - 1.7 vs - 1.3; P = 0.002), reduced abdominal pain (- 1.7 vs - 1.3; P = 0.006), and increased CSBM frequency (1.4 vs 0.8; P < 0.0001). In the mild bloating subgroup, significant improvements were observed with plecanatide versus placebo for abdominal pain (LSMC: - 1.3 vs - 1.0; P = 0.046) and CSBM frequency (2.0 vs 1.2; P = 0.003) but not bloating (- 0.9 vs - 0.8; P = 0.28). A significantly greater percentage of patients were abdominal pain and bloating composite responders with plecanatide versus placebo (moderate-to-severe bloating: 33.6% vs 26.8% [P = 0.02]; mild bloating: 38.4% vs 27.2% [P = 0.03]). CONCLUSION: Plecanatide treatment improved IBS-C abdominal and bowel symptoms, including in those who present with moderate-to-severe bloating.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeConstipationAbdominal PainNatriuretic PeptidesHumansMaleFemaleMiddle AgedAdultTreatment OutcomeSeverity of Illness IndexDefecationDouble-Blind MethodGastrointestinal Agents

Stichwörter der Autor:innen

Abdominal painBloatingConstipationGastrointestinal motilityGuanylyl cyclase C agonistsIrritable bowel syndrome

Substanzen

Natriuretic PeptidesGastrointestinal Agentsplecanatide

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Darren.brenner@nm.org.
  • Division of Gastroenterology and Hepatology, Digestive Health Center, Augusta University, Augusta, GA, USA.
  • Salix Pharmaceuticals, Bridgewater, NJ, USA.
  • Division of Gastroenterology and Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
  • Gastroenterology Section, John Cochran Veterans Affairs Medical Center, St. Louis, MO, USA.

Förderung

  • Salix Pharmaceuticals

Zitieren

APA

Brenner, D. M., Sharma, A., Rao, S. S. C., Laitman, A. P., Heimanson, Z., Allen, C., & Sayuk, G. S. (2024). Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08330-y

Vancouver

Brenner DM, Sharma A, Rao SSC, Laitman AP, Heimanson Z, Allen C, et al. Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08330-y

BibTeX
@article{Brenner2024,
  author = {Brenner, Darren M and Sharma, Amol and Rao, Satish S C and Laitman, Adam P and Heimanson, Zeev and Allen, Christopher and Sayuk, Gregory S},
  title = {Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation},
  journal = {Digestive Diseases and Sciences},
  year = {2024},
  doi = {10.1007/s10620-024-08330-y}
}
Kostenlos starten →